1. Home
  2. COO vs INCY Comparison

COO vs INCY Comparison

Compare COO & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Cooper Companies Inc.

COO

The Cooper Companies Inc.

HOLD

Current Price

$81.98

Market Cap

15.5B

Sector

Health Care

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$102.46

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COO
INCY
Founded
1980
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.5B
17.0B
IPO Year
N/A
1993

Fundamental Metrics

Financial Performance
Metric
COO
INCY
Price
$81.98
$102.46
Analyst Decision
Buy
Buy
Analyst Count
11
20
Target Price
$85.82
$90.71
AVG Volume (30 Days)
3.3M
2.0M
Earning Date
12-04-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
3878.02
EPS
1.87
5.90
Revenue
$4,092,400,000.00
$4,813,105,000.00
Revenue This Year
$6.66
$19.59
Revenue Next Year
$5.54
$10.88
P/E Ratio
$43.53
$17.37
Revenue Growth
5.06
18.09
52 Week Low
$61.78
$53.56
52 Week High
$104.47
$109.28

Technical Indicators

Market Signals
Indicator
COO
INCY
Relative Strength Index (RSI) 72.89 54.83
Support Level $75.25 $100.55
Resistance Level $78.69 $107.61
Average True Range (ATR) 2.48 2.94
MACD 0.47 -0.98
Stochastic Oscillator 55.39 45.19

Price Performance

Historical Comparison
COO
INCY

About COO The Cooper Companies Inc.

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: